Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Peringkat dalam Saham
#3773
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Harga Saham
$4.87
Kapitalisasi Pasar
$4.36B
Perubahan (1 hari)
-5.47%
Perubahan (1 tahun)
-15.62%
Negara
CN
Perdagangan Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Kategori
Healthcare
Riwayat harga saham Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Harga penutupan tertinggi: $5.19 pada 2026-10-01
Harga penutupan terendah: $4.81 pada 2020-07-01
Harga penutupan terendah: $4.81 pada 2020-07-01
Riwayat harga saham Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd dari 2020 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | 6.67% |
| 2025 | 188.76% |
| 2024 | -5.91% |
| 2023 | 62.34% |
| 2022 | -30.84% |
| 2021 | -25.95% |
| 2020 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
